AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15908760 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (postirritation) once a day for 5 days
Number of subjects: 0
Study 11994110 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier Endosheath system
Number of subjects: 0
Study 11994110 — intervention group
Group type: COMPARATOR
Intervention: Immersion in Cidex disinfectant
Number of subjects: 0
Study 9667295 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 40
Study 9667295 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 40
Study 9667295 — intervention group
Group type: COMPARATOR
Intervention: Head-up position (after norepinephrine or phenylephrine infusion)
Number of subjects: 40
Study 7660342 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 200 micrograms aqueous nasal spray administered twice daily for two weeks
Number of subjects: 24
Study 7660342 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 24
Study 2636858 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee
Number of subjects: 13
Study 2636858 — intervention group
Group type: COMPARATOR
Intervention: Herbal Tea (Control)
Number of subjects: 13
Study 996687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxamniquine at a total dose of 60 mg/kg (given in 4 equal doses morning and evening over 2 days, after food)
Number of subjects: 0
Study 996687 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses or shorter schedules of treatment
Number of subjects: 0
Study 996687 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxamniquine
Number of subjects: 0
Study 31990972 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated energy drink
Number of subjects: 223
Study 31990972 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 223
Study 29742935 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 64
Study 29742935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 64
Study 29742935 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 64
Study 27754927 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI trajectories leading to obesity
Number of subjects: 69873
Study 27754927 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI at age 20 years, 50 years, and baseline questionnaire
Number of subjects: 69873
Study 27754927 — intervention group
Group type: COMPARATOR
Intervention: BMI trajectories
Number of subjects: 69873
Study 26016699 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg/daily for 1 week and then for the first 2 days of every month for the following 3 months
Number of subjects: 68
Study 26016699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 23937748 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plating osteosynthesis
Number of subjects: 47
Study 23937748 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary nailing (IMN)
Number of subjects: 47
Study 21941878 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of captions
Number of subjects: 62
Study 21941878 — intervention group
Group type: COMPARATOR
Intervention: No captions (Control)
Number of subjects: 62
Study 19253239 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with peripheral iridectomy
Number of subjects: 47
Study 19253239 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaco-trabeculectomy with peripheral iridectomy
Number of subjects: 47
Study 19253239 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy without peripheral iridectomy
Number of subjects: 47
Study 19253239 — intervention group
Group type: COMPARATOR
Intervention: Phaco-trabeculectomy without peripheral iridectomy
Number of subjects: 47
Study 16393306 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg administered i.v. over 20 min
Number of subjects: 10
Study 16393306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15233978 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/benazepril combination therapy (5 mg and 10 mg with 40 mg benazepril)
Number of subjects: 0
Study 15233978 — intervention group
Group type: COMPARATOR
Intervention: Benazepril hydrochloride (40 mg) alone
Number of subjects: 0
Study 11316720 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral famciclovir 500 mg three times daily
Number of subjects: 454
Study 11316720 — intervention group
Group type: COMPARATOR
Intervention: Oral aciclovir 800 mg five times daily
Number of subjects: 454
Study 9159566 — intervention group
Group type: COMPARATOR
Intervention: Dopamine 0 microg kg(‐1) min(‐1) (placebo)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 1 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 2 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 3 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 5 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 7.5 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 10 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 9159566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine 12.5 microg kg(‐1) min(‐1)
Number of subjects: 8
Study 7967191 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-IMP SPECT
Number of subjects: 19
Study 7967191 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 19
Study 7967191 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG
Number of subjects: 19
Study 3555587 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg twice daily
Number of subjects: 12
Study 3555587 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 50 mg + hydrochlorothiazide (HCTZ) 25 mg once daily
Number of subjects: 12
Study 3555587 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily
Number of subjects: 12
Study 30917183 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests from affluent constituents
Number of subjects: 0
Study 30917183 — intervention group
Group type: EXPERIMENTAL
Intervention: Requests from poor constituents
Number of subjects: 0
Study 28662731 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched foods and drinks (12-week intervention)
Number of subjects: 75
Study 26215901 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time feedback (inertial sensor)
Number of subjects: 61
Study 26215901 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (no feedback)
Number of subjects: 61
Study 23434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deprivation for up to 66 hours
Number of subjects: 45
Study 23434165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation for up to 50 hours
Number of subjects: 45
Study 23434165 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived instructors
Number of subjects: 45
Study 21973229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 127
Study 18058818 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg/day for 10-14 days before surgery
Number of subjects: 53
Study 18058818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NSAID)
Number of subjects: 53
Study 18058818 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 53
Study 16937589 — intervention group
Group type: EXPERIMENTAL
Intervention: TB + Flossing (TB + Fl)
Number of subjects: 102
Study 16937589 — intervention group
Group type: COMPARATOR
Intervention: Tongue brushing and toothbrushing (TB)
Number of subjects: 102
Study 16937589 — intervention group
Group type: EXPERIMENTAL
Intervention: TB + Fl
Number of subjects: 102
Study 16937589 — intervention group
Group type: COMPARATOR
Intervention: TB
Number of subjects: 102
Study 15319157 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac‐Na 0.1% Emulgel gel
Number of subjects: 172
Study 15319157 — intervention group
Group type: COMPARATOR
Intervention: vehicle Emulgel gel
Number of subjects: 172
Study 11149011 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly i.v. bolus injection of 5‐fluorouracil 400 mg/m2 plus leucovorin 20 mg/m2
Number of subjects: 96
Study 11149011 — intervention group
Group type: COMPARATOR
Intervention: Monthly i.v. bolus injection of 5‐fluorouracil 425 mg/m2 plus leucovorin 20 mg/m2 for 5 consecutive days every 4 or 5 weeks
Number of subjects: 96
Study 11149011 — intervention group
Group type: COMPARATOR
Intervention: Monthly arm
Number of subjects: 96
Study 9076817 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole gel (25 mg, four times daily)
Number of subjects: 227
Study 8407753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methylphenidate and desipramine
Number of subjects: 0
Study 8407753 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine alone
Number of subjects: 0
Study 3948857 — intervention group
Group type: EXPERIMENTAL
Intervention: WIEXP (water immersion with blood volume expansion by intravenous infusion of 2.0 L of isotonic saline for 2 hours)
Number of subjects: 8
Study 3948857 — intervention group
Group type: COMPARATOR
Intervention: WIHEM (water immersion with blood volume reduction by loss of 0.5 L of blood during 30 minutes)
Number of subjects: 8
Study 29723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline violence
Number of subjects: 1090
Study 29723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline alcohol misuse
Number of subjects: 1090
Study 29723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Increases in PTSD symptoms between Waves 1 and 2
Number of subjects: 1090
Study 29723020 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreases in social support between Waves 1 and 2
Number of subjects: 1090
Study 27630503 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA) combined with platelet-rich fibrin (PRF)
Number of subjects: 36
Study 27630503 — intervention group
Group type: COMPARATOR
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 36
Study 25265927 — intervention group
Group type: EXPERIMENTAL
Intervention: DECT mode, 0.5 ml per kg of patient weight CM at injection rate=(weight × 0.5 ml/kg)/(4+scan time)
Number of subjects: 60
Study 25265927 — intervention group
Group type: COMPARATOR
Intervention: Single‐energy CT 70 ml CM at injection rate of 5 ml/s
Number of subjects: 60
Study 21900307 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire using the word 'placebo'
Number of subjects: 190
Study 21900307 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire using the term 'nonspecific methods of treatment'
Number of subjects: 190
Study 19557486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated outflow cannula
Number of subjects: 28
Study 19557486 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulae
Number of subjects: 28
Study 17288679 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based therapy
Number of subjects: 9193
Study 17288679 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based therapy
Number of subjects: 9193
Study 17288679 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 9193
Study 17288679 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg plus hydrochlorothiazide 12.5 mg
Number of subjects: 9193
Study 16053996 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (low-dose angiotensin receptor blocker) for 2 years
Number of subjects: 809
Study 16053996 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 809
Study 11876701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (20 mg)
Number of subjects: 230
Study 11876701 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (40 mg)
Number of subjects: 230
Study 11030815 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative application of mitomycin (group 1)
Number of subjects: 22
Study 11030815 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative application of mitomycin (group 2)
Number of subjects: 22
Study 11030815 — intervention group
Group type: COMPARATOR
Intervention: No mitomycin application (group 3)
Number of subjects: 22
Study 8674397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg four times a day)
Number of subjects: 10
Study 8674397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1456569 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (500 mg)
Number of subjects: 7
Study 1456569 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (80 mg)
Number of subjects: 7
Study 1456569 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 7
Study 3881327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 750 mg daily
Number of subjects: 160
Study 3881327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid 375 mg daily
Number of subjects: 160
Study 3881327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 30580675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancement (IE) intervention
Number of subjects: 29
Study 30580675 — intervention group
Group type: COMPARATOR
Intervention: Educational control condition
Number of subjects: 29
Study 29744900 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (loading dose 25 mg kg‐1; maintenance dose 12 mg kg‐1 day‐1 for infants <30 weeks or 20 mg kg‐1 day‐1 for infants ≥30 weeks' corrected gestational age)
Number of subjects: 36
Study 29744900 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (loading dose 15 mg kg‐1 day‐1; maintenance dose 10 mg kg‐1 day‐1)
Number of subjects: 36
Study 27098825 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face individual counselling plus telephone follow-up counselling (FCF group)
Number of subjects: 457
Study 27098825 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face individual counselling (FC group)
Number of subjects: 457
Study 25449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 464
Study 25449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Perphenazine
Number of subjects: 464
Study 25449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 464
Study 25449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 464
Study 25449714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 464
Study 23130467 — intervention group
Group type: EXPERIMENTAL
Intervention: Split drug regimen (two times a day)
Number of subjects: 122
Study 23130467 — intervention group
Group type: COMPARATOR
Intervention: Once daily regimen
Number of subjects: 122
Study 20102935 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10001
Study 20102935 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10001
Study 18840838 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-point ultrasonography
Number of subjects: 2098
Study 18840838 — intervention group
Group type: COMPARATOR
Intervention: Whole-leg ultrasonography
Number of subjects: 2098
Study 16278523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 22576
Study 16278523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil
Number of subjects: 22576
Study 16278523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (verapamil/trandolapril or atenolol/hydrochlorothiazide)
Number of subjects: 22576
Study 16278523 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (verapamil/trandolapril/hydrochlorothiazide or atenolol/hydrochlorothiazide/trandolapril)
Number of subjects: 22576
Study 16278523 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (verapamil or atenolol)
Number of subjects: 22576
Study 12443949 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with knee pain
Number of subjects: 0
Study 12443949 — intervention group
Group type: COMPARATOR
Intervention: Subjects without knee pain
Number of subjects: 0
Study 10707135 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg anthocyanosides
Number of subjects: 18
Study 10707135 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 mg anthocyanosides
Number of subjects: 18
Study 10707135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8560999 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg estradiol valerate
Number of subjects: 7
Study 8560999 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg norethisterone acetate
Number of subjects: 7
Study 8560999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30146446 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 157
Study 30146446 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (0.9% sodium chloride)
Number of subjects: 157
Study 27911117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 70
Study 27911117 — intervention group
Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 70
Study 25576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated measurement of QT and RR during continuous 24-h electrocardiogram recordings
Number of subjects: 49
Study 25576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement on 10-s electrocardiograms
Number of subjects: 49
Study 25576068 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated method
Number of subjects: 49
Study 25576068 — intervention group
Group type: COMPARATOR
Intervention: Manual method
Number of subjects: 49
Study 23810097 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 0
Study 23810097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21795660 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 406
Study 21795660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study 18581513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA) 40 mg/kg intravenously
Number of subjects: 250
Study 18581513 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (DCA)
Number of subjects: 250
Study 18581513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 15942580 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon thermoregulation system (AT group)
Number of subjects: 90
Study 15942580 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care (RTC group)
Number of subjects: 90
Study 12861460 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training program
Number of subjects: 193
Study 12861460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 193
Study 10802158 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat diet
Number of subjects: 23
Study 8806289 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radical radiotherapy (50 Gy to breast with boost to the tumour bed)
Number of subjects: 585
Study 8806289 — intervention group
Group type: COMPARATOR
Intervention: No further local treatment
Number of subjects: 585
Study 1503329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 95)
Number of subjects: 187
Study 1503329 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (n = 92)
Number of subjects: 187
Study 6427416 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - simultaneous administration
Number of subjects: 239
Study 6427416 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM combination (5‐fluorouracil, doxorubicin, and mitomycin C) - sequential administration
Number of subjects: 239
Study 6427416 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degrees of hematologic toxicity
Number of subjects: 239
Study 6427416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients treated by community oncologists
Number of subjects: 239
Study 6427416 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior exposure to 5‐fluorouracil
Number of subjects: 239
Study 30827300 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral massage method with non-nutritive sucking, stimulating swallowing function, and SandraFucile, once a day for 14 consecutive days.
Number of subjects: 151
Study 30827300 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment of preterm infants without oral intervention.
Number of subjects: 151
Study 29086614 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (600 mg)
Number of subjects: 32
Study 29086614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26460632 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPO (FiO2 ≈ 0.155)
Number of subjects: 11
Study 26460632 — intervention group
Group type: COMPARATOR
Intervention: NORM
Number of subjects: 11
Study 26460632 — intervention group
Group type: EXPERIMENTAL
Intervention: N + H analysis
Number of subjects: 11
Study 24365208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ergometrine (0.5mg)
Number of subjects: 0
Study 24365208 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxytocin (10 IU)
Number of subjects: 0
Study 22810989 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine fortified with EPA (10 weight percent)
Number of subjects: 74
Study 22810989 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine fortified with DHA (10 weight percent)
Number of subjects: 74
Study 22810989 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine fortified with ALA (10 weight percent)
Number of subjects: 74
Study 20799900 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair massage (n=40)
Number of subjects: 82
Study 20799900 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control (n=42)
Number of subjects: 82